Toxicologie, Pharmacologie et Signalisation céllulaire - UMR-S 1124
Université Paris Descartes
45 rue des Saints Pères
75270 Paris Cedex 06
Fax : +33 (0) 1 42 86 38 68
New therapeutic approaches of the myelinisation
alex.carrete@-Code to remove to avoid SPAM-parisdescartes.fr
+33 1 42 86 22 73, room H344
Alex Carreté, a first year Ph.D. student in the team of Prof. Charbel Massaad, studies the molecular and cellular mechanisms consecutive to a demyelination of the central nervous system. Using ex vivo and in vivo models, his goal is to develop a therapeutic strategy via a pharmacological compound that has remylinating properties
I obtained my Bachelor’s degree at the Paris Descartes University. During the three years of study for this degree, I took courses in neuroscience. Then, I spent the first year of my Master’s degree studies at the University of Tours, a year during which I completed an internship in the laboratory of Prof. Catherine Belzung. I studied the mechanisms which underlie depression and the beneficial effects of spatial learning in a mouse model of depression. Then, I chose to do the second year of study for my Master’s degree in Marseille. During a 6-month internship in the laboratory of Prof. Santiago Rivera, I worked on a mouse model of Alzheimer’s disease (5xFAD). I studied the beneficial effects of a total knockout of the MT5-MMP protein, a matrix metalloproteinase which is found specifically in the central nervous system.
At present, I am a Ph.D. student in the team of Prof. Charbel Massaad (group of Prof. M. Jafarian-Tehrani). I study oligodendrocyte responses to different types of demyelinating lesions (toxic and traumatic) in several models (in vitro, ex vivo and in vivo). Following recent studies conducted by the team, I have focused my interest specifically on a pharmacological compound that has remylinating properties in response to demyelination. I’ve always been fascinated by the brain and the neurodegenerative diseases. Our knowledge of these diseases is still limited and the urgency to find effective therapeutic strategies for these disorders makes this subject very exciting. I intend to further explore this area upon completion of my Ph.D. degree.
- Targeting demyelination via α-secretases promoting sAPPα release to enhance remyelination in central nervous system.
Llufriu-Dabén G, Carrete A, Chierto E, Mailleux J, Camand E, Simon A, Vanmierlo T, Rose C, Allinquant B, Hendriks JJA, Massaad C, Meffre D, Jafarian-Tehrani M : Neurobiol Dis, 2017